Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
$0.60
$0.60
$0.59
$0.60
$31.81M-0.131 shsN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$167.08M0.53600 shsN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$2.23
$2.22
$1.29
$3.65
$127.82M1.7724,253 shsN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
$0.31
$0.30
$0.22
$1.14
$53.51M0.931.01 million shs2.68 million shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.65
+4.0%
$17.60
$12.12
$26.99
$53.66M0.5822,908 shs4,836 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00%0.00%0.00%+31.90%+335.73%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%-22.00%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00%0.00%0.00%0.00%0.00%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
+6.06%+9.13%-3.96%-13.60%-11.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.9833 of 5 stars
3.54.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00
N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00
N/AN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00
N/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50113.21% Upside

Current Analyst Ratings Breakdown

Latest VTVT, TYME, PRTK, HBPCF, and NWPHF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$160.27M0.80N/AN/A($3.08) per share-0.72
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/A$0.47 per shareN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M52.07N/AN/A$4.48 per share3.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
-$6.82M-$0.14N/AN/AN/AN/A-747.46%N/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
-$63.57M-$1.10N/AN/A-35.44%N/A-40.05%N/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
-$23.63M-$0.14N/AN/AN/A-28.30%-26.21%N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.01N/AN/AN/A-121.46%-46.75%8/6/2025 (Estimated)

Latest VTVT, TYME, PRTK, HBPCF, and NWPHF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/16/2025Q3 2025
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A-$0.02N/A-$0.02N/AN/A
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
0.42
0.42
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/A
0.52
0.46
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/A
14.06
14.06
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
7.39
7.39
CompanyEmployeesShares OutstandingFree FloatOptionable
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
953.02 million48.99 millionNot Optionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
26857.32 million52.74 millionOptionable
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
17172.21 million143.10 millionOptionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Helix Biopharma stock logo

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)
As of 07/8/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 07/8/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Paratek Pharmaceuticals stock logo

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Tyme Technologies stock logo

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.65 +0.64 (+4.00%)
As of 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.